Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Liver Neoplasms 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 2Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 28pembrolizumab 24Cisplatin 24Fluorouracil 11Leucovorin 10Oxaliplatin 8Nivolumab 7Capecitabine 6Irinotecan 5Drug Therapy 5pemigatinib 4futibatinib 4Paclitaxel 4Carboplatin 4ivosidenib 3durvalumab 3derazantinib 3Folfox protocol 3Bevacizumab 3zanidatamab 2spartalizumab 2olutasidenib 2lenvatinib 2infigratinib 2fludarabine 2budigalimab 2Trastuzumab 2Ipilimumab 2Injections 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Cholangiocarcinoma × derazantinib × Clear all
NCT04087876 2025-04-06

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Basilea Pharmaceutica

No longer available
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT03230318 2023-12-19

FIDES-01

Basilea Pharmaceutica

Phase 2 Completed
148 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Basilea Pharmaceutica

Phase 1/2 Completed
119 enrolled 15 charts
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡